AstraZeneca-Alexion US clearance shows big pharma deals can still avoid deep probes
The clearance of AstraZeneca’s acquisition of Alexion by the Federal Trade Commission shows that large pharmaceutical deals can still escape lengthy scrutiny during the Biden administration despite promises for tougher enforcement....
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: